JP2006508942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508942A5 JP2006508942A5 JP2004548591A JP2004548591A JP2006508942A5 JP 2006508942 A5 JP2006508942 A5 JP 2006508942A5 JP 2004548591 A JP2004548591 A JP 2004548591A JP 2004548591 A JP2004548591 A JP 2004548591A JP 2006508942 A5 JP2006508942 A5 JP 2006508942A5
- Authority
- JP
- Japan
- Prior art keywords
- equol
- androgen
- binding
- mammal
- enantiomeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims 27
- 235000019126 equol Nutrition 0.000 claims 22
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims 22
- 238000000034 method Methods 0.000 claims 18
- 241000124008 Mammalia Species 0.000 claims 16
- 239000003098 androgen Substances 0.000 claims 15
- 230000027455 binding Effects 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims 10
- ADFCQWZHKCXPAJ-LBPRGKRZSA-N (R)-Equol Chemical class C1=CC(O)=CC=C1[C@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-LBPRGKRZSA-N 0.000 claims 7
- 102000001307 androgen receptors Human genes 0.000 claims 7
- 108010080146 androgen receptors Proteins 0.000 claims 7
- 229940088597 hormone Drugs 0.000 claims 6
- 239000005556 hormone Substances 0.000 claims 6
- 229940011871 estrogen Drugs 0.000 claims 5
- 239000000262 estrogen Substances 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000004963 pathophysiological condition Effects 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 2
- 206010017065 Foster-Kennedy Syndrome Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010051246 Photodermatosis Diseases 0.000 claims 2
- 208000012641 Pigmentation disease Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 230000003712 anti-aging effect Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000012875 competitive assay Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 230000001815 facial effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000004132 lipogenesis Effects 0.000 claims 2
- 230000004130 lipolysis Effects 0.000 claims 2
- 230000004630 mental health Effects 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000008845 photoaging Effects 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 210000001732 sebaceous gland Anatomy 0.000 claims 2
- 210000002374 sebum Anatomy 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 230000037075 skin appearance Effects 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000007698 birth defect Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 230000002087 whitening effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42246902P | 2002-10-29 | 2002-10-29 | |
| US60/422,469 | 2002-10-29 | ||
| PCT/US2003/034441 WO2004039327A2 (en) | 2002-10-29 | 2003-10-29 | Use of equol for treating androgen mediated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011177316A Division JP5535999B2 (ja) | 2002-10-29 | 2011-08-12 | アンドロゲンによって仲介される疾患を治療するためのエクオールの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508942A JP2006508942A (ja) | 2006-03-16 |
| JP2006508942A5 true JP2006508942A5 (https=) | 2006-12-28 |
| JP4889944B2 JP4889944B2 (ja) | 2012-03-07 |
Family
ID=32230355
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004548591A Expired - Lifetime JP4889944B2 (ja) | 2002-10-29 | 2003-10-29 | アンドロゲンによって仲介される疾患を治療するためのエクオールの使用 |
| JP2011177316A Expired - Fee Related JP5535999B2 (ja) | 2002-10-29 | 2011-08-12 | アンドロゲンによって仲介される疾患を治療するためのエクオールの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011177316A Expired - Fee Related JP5535999B2 (ja) | 2002-10-29 | 2011-08-12 | アンドロゲンによって仲介される疾患を治療するためのエクオールの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US20060122262A1 (https=) |
| EP (1) | EP1569636B1 (https=) |
| JP (2) | JP4889944B2 (https=) |
| AU (1) | AU2003286781B2 (https=) |
| CA (1) | CA2504682A1 (https=) |
| WO (1) | WO2004039327A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050245492A1 (en) * | 2004-04-28 | 2005-11-03 | Lephart Edwin D | Use of equol for treating skin diseases |
| EP1545206B1 (en) | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
| US8668914B2 (en) * | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| CA2504682A1 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
| EP1649760B1 (en) | 2003-06-30 | 2013-05-22 | Otsuka Pharmaceutical Co., Ltd. | Composition containing lactic acid bacterium producing equol |
| CA2617031A1 (en) * | 2005-07-29 | 2007-02-01 | Calpis Co., Ltd. | Prophylactic/ameliorating agent for menopausal disorder and functional beverage/food |
| US7528267B2 (en) | 2005-08-01 | 2009-05-05 | Girindus America, Inc. | Method for enantioselective hydrogenation of chromenes |
| NL1030571C2 (nl) * | 2005-12-01 | 2006-04-27 | Sara Lee De Nv | Geurafgiftesysteem. |
| US8680140B2 (en) * | 2006-08-02 | 2014-03-25 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms |
| CA2660056A1 (en) * | 2006-08-18 | 2008-02-21 | Colorado State University Research Foundation | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| US20100280231A1 (en) * | 2007-04-09 | 2010-11-04 | Masayuki Nakano | Whitening agent comprising equol or its saccharide derivative as an effective ingredient |
| WO2008153158A1 (ja) * | 2007-06-13 | 2008-12-18 | Otsuka Pharmaceutical Co., Ltd. | エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品 |
| AU2009282482B2 (en) * | 2008-08-15 | 2015-11-26 | Société des Produits Nestlé S.A. | Methods for enhancing energy metabolism |
| US20110091435A1 (en) * | 2008-10-24 | 2011-04-21 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of hair loss |
| EP2898923A3 (en) * | 2011-04-15 | 2015-10-07 | Nestec S.A. | Isoflavones for regulating sirtuin gene expression |
| JP2014515756A (ja) * | 2011-04-20 | 2014-07-03 | ネステク ソシエテ アノニム | 高レプチン血症の予防及び治療に適した方法及び組成物 |
| KR20160026042A (ko) * | 2014-08-29 | 2016-03-09 | (주)아모레퍼시픽 | 락토비온산을 함유하는 항스트레스용 또는 항상성 유지용 조성물 |
| JP2017531025A (ja) * | 2014-10-14 | 2017-10-19 | ジャクソン，リチャード・エル | Ｓ−エクオールの無水結晶形 |
| US10391079B2 (en) * | 2016-07-26 | 2019-08-27 | Ausio Pharmaceuticals, Llc | Methods of diagnosing and treating Alzheimer's disease with S-equol |
| AU2019285640A1 (en) | 2018-06-15 | 2021-01-21 | Board Of Regents Of The University Of Texas System | Methods of treating and preventing breast cancer with S-equol |
| WO2019240872A1 (en) | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| EP4138921A1 (en) * | 2020-04-23 | 2023-03-01 | University Of Iowa Research Foundation | Gper proteolytic targeting chimeras |
| US20230190702A1 (en) * | 2020-05-21 | 2023-06-22 | Daicel Corporation | A composition for improving qol of a 40-year-old or older postmenopausal woman without menopausal disorder |
| US20230310367A1 (en) * | 2020-09-04 | 2023-10-05 | Daicel Corporation | Composition for enhancing nampt gene expression |
| CN116531393A (zh) * | 2023-04-03 | 2023-08-04 | 河北医科大学 | 一种预防高热惊厥发作的药物组合物 |
| JP7596493B1 (ja) * | 2023-11-24 | 2024-12-09 | 株式会社ダイセル | 男性のｑｏｌの改善のための組成物 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4390559A (en) * | 1979-04-11 | 1983-06-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
| US5468501A (en) | 1982-09-01 | 1995-11-21 | Hercon Laboratories Corporation | Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant |
| USRE34457E (en) * | 1983-12-28 | 1993-11-30 | Daicel Chemical Industries, Inc. | Separating agent |
| GB8626344D0 (en) * | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
| JPH02124883A (ja) | 1988-11-04 | 1990-05-14 | Kitasato Inst:The | 抗酸化作用を有するイソフラボン誘導体およびその製造法 |
| CH679584A5 (https=) * | 1989-11-10 | 1992-03-13 | Nestle Sa | |
| TW279133B (https=) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| DE69333624T2 (de) * | 1992-05-19 | 2005-09-15 | Novogen Research Pty. Ltd., North Ryde | Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee |
| CA2160371A1 (en) * | 1993-04-16 | 1994-10-27 | The Trustees Of Tufts College | Method for treatment of menopausal and premenstrual symptoms |
| US5613958A (en) | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| US5320949A (en) * | 1993-10-12 | 1994-06-14 | Protein Technologies International, Inc. | Process for producing aglucone isoflavone enriched vegetable protein fiber |
| US5424331A (en) * | 1994-06-10 | 1995-06-13 | Bio-Virus Research Incorporated | Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis |
| WO1996010341A1 (en) | 1994-10-03 | 1996-04-11 | Schouten Industries B.V. | Food and health products |
| US5523087A (en) * | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
| AUPN166195A0 (en) * | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
| FR2731706B1 (fr) * | 1995-03-14 | 1997-04-11 | Cird Galderma | Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
| US5554519A (en) | 1995-08-07 | 1996-09-10 | Fermalogic, Inc. | Process of preparing genistein |
| US5693018A (en) | 1995-10-11 | 1997-12-02 | Science Incorporated | Subdermal delivery device |
| US5821361A (en) * | 1996-06-11 | 1998-10-13 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
| AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US5726034A (en) * | 1996-09-06 | 1998-03-10 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same |
| US5804234A (en) * | 1996-09-13 | 1998-09-08 | Suh; John D. | Plant protein for nutritional products and method of making same |
| US6020471A (en) * | 1996-09-13 | 2000-02-01 | Abbott Laboratories | Process for isolating phytoestrogens from plant protein |
| WO1998021946A1 (en) | 1996-11-18 | 1998-05-28 | Internutria, Inc. | Composition and treatment for persistent reproductive transition symptoms |
| US5733926A (en) * | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
| AUPO427196A0 (en) * | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
| AU7165798A (en) * | 1997-04-28 | 1998-11-24 | Anticancer, Inc. | Use of genistein and related compounds to treat certain sex hormone related conditions |
| US6146668A (en) * | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
| WO1998050026A1 (en) * | 1997-05-01 | 1998-11-12 | Novogen Inc | Treatment or prevention of menopausal symptoms and osteoporosis |
| US6083526A (en) * | 1997-05-22 | 2000-07-04 | Gorbach; Sherwood L. | Use of isoflavonoids in the treatment or prevention of postpartum depression |
| US6060070A (en) * | 1997-06-11 | 2000-05-09 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
| DE69832516T2 (de) * | 1997-08-08 | 2006-07-27 | Otsuka Pharmaceutical Co., Ltd. | Isoflavon-enthaltende zusammensetzungen |
| US6521433B1 (en) * | 1997-09-17 | 2003-02-18 | E. I. Du Pont De Nemours And Company | cDNA sequences from plants that encode activities associated with isoflavone biosynthesis |
| US5855892A (en) * | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
| US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
| US5942539A (en) * | 1997-10-03 | 1999-08-24 | Wake Forest University | Methods of treating or preventing endometriosis with phytoestrogens |
| AUPP112497A0 (en) | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
| US5958946A (en) * | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
| US6004558A (en) * | 1998-02-25 | 1999-12-21 | Novogen, Inc. | Methods for treating cancer with legume plant extracts |
| AUPP260798A0 (en) * | 1998-03-26 | 1998-04-23 | Novogen Research Pty Ltd | Treatment of medical related conditions with isoflavone containing extracts of clover |
| US6086915A (en) | 1998-04-01 | 2000-07-11 | Bioresponse L.L.C. | Compositions and methods of adjusting steroid hormone metabolism through phytochemicals |
| AU4204099A (en) | 1998-05-27 | 1999-12-13 | Sherwood L. Gorbach | Isoflavonoids for treatment and prevention of migraine headaches |
| BR9906998A (pt) | 1998-09-10 | 2000-09-26 | Avon Prod Inc | Método e composições para reduzir o envelhecimento dermatológico e para reduzir contusões |
| WO2000030663A1 (en) | 1998-11-25 | 2000-06-02 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |
| WO2000030664A1 (en) * | 1998-11-25 | 2000-06-02 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
| EP1146798A2 (en) | 1999-01-15 | 2001-10-24 | Nutrahealth Ltd. (UK) | Modified food products and beverages, and additives for food and beverages |
| AUPP868599A0 (en) | 1999-02-15 | 1999-03-11 | Novogen Research Pty Ltd | Production of isoflavone derivatives |
| EE200100526A (et) * | 1999-04-16 | 2002-12-16 | Astrazeneca Ab | Östrogeeni ß-retseptori ligandid |
| CA2368784A1 (en) | 1999-04-20 | 2000-10-26 | William J. Banz | Methods of treating clinical diseases with isoflavones |
| US6544566B1 (en) * | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
| AU4689600A (en) | 1999-05-04 | 2000-11-17 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| US6401125B1 (en) | 1999-08-05 | 2002-06-04 | Nextpage, Inc. | System and method for maintaining state information between a web proxy server and its clients |
| US6375994B1 (en) * | 1999-08-20 | 2002-04-23 | Sun Ten Laboratories, Inc. | Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability |
| EP1414436A1 (en) * | 2000-06-14 | 2004-05-06 | Alla Shapiro | Radioprotective agents |
| US6455568B2 (en) * | 2000-07-06 | 2002-09-24 | Wyeth | Combination therapy for inhibiting sphincter incontinence |
| MXPA02012897A (es) | 2000-07-06 | 2003-10-24 | Wyeth Corp | Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos. |
| JP2004502731A (ja) | 2000-07-06 | 2004-01-29 | ワイス | スタチン、エストロゲン剤および所望によるエストロゲンの組み合わせ |
| AU2001271784A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Therapy for prosthesis-related bone degeneration |
| AU2001283322A1 (en) | 2000-08-10 | 2002-02-18 | M. D. Brian D. Zelickson | Organic nutrient for hair loss treatment |
| US6326366B1 (en) * | 2000-08-22 | 2001-12-04 | Protein Technologies International | Hormone replacement therapy |
| US20020143059A1 (en) | 2000-12-28 | 2002-10-03 | Sreekumar Pillai | Skin care product containing retinoids, retinoid booster and phytoestrogens in a dual compartment package |
| US6565864B2 (en) * | 2000-12-28 | 2003-05-20 | Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. | Skin care product containing retinoids and phytoestrogens in a dual compartment package |
| US20020192310A1 (en) | 2001-02-02 | 2002-12-19 | Bland Jeffrey S. | Medical composition for managing hormone balance |
| CN1526027A (zh) * | 2001-02-02 | 2004-09-01 | ̹�� | 综合性金属加工设备 |
| EP1234572B1 (de) * | 2001-02-26 | 2013-10-30 | Mibelle AG Cosmetics | Isoflavon-Aglykone enhaltende Hautbehandlungsmittel |
| US6638543B2 (en) | 2001-02-27 | 2003-10-28 | Regents Of The University Of Michigan | Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor |
| DE10121375B4 (de) | 2001-05-02 | 2014-01-16 | Beiersdorf Ag | Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut |
| DE10122342A1 (de) | 2001-05-09 | 2002-11-14 | Beiersdorf Ag | Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen |
| FR2825277B1 (fr) | 2001-05-30 | 2004-10-15 | Oreal | Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd |
| US6597597B2 (en) * | 2001-11-13 | 2003-07-22 | Hewlett-Packard Company | Low temperature attaching process for MRAM components |
| US20050245492A1 (en) * | 2004-04-28 | 2005-11-03 | Lephart Edwin D | Use of equol for treating skin diseases |
| US8668914B2 (en) * | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| EP1545206B1 (en) * | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
| AU2002951271A0 (en) | 2002-09-06 | 2002-09-19 | Novogen Research Pty Ltd | Repair of dna mutagenic damage |
| US20060153782A1 (en) | 2002-09-23 | 2006-07-13 | Novogen Research Pty Ltd | Skin photoageing and actinic damage treatment |
| US8580846B2 (en) * | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| CA2504682A1 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
| US7528267B2 (en) * | 2005-08-01 | 2009-05-05 | Girindus America, Inc. | Method for enantioselective hydrogenation of chromenes |
| EP1961309A4 (en) | 2005-12-06 | 2010-01-20 | Otsuka Pharma Co Ltd | EMBRYONIC AXIS FERMENTATION PRODUCT OF SOYBEAN CONTAINING EQUOL, AND METHOD FOR PRODUCING THE SAME |
-
2003
- 2003-10-29 CA CA002504682A patent/CA2504682A1/en not_active Abandoned
- 2003-10-29 EP EP03777994.9A patent/EP1569636B1/en not_active Expired - Lifetime
- 2003-10-29 WO PCT/US2003/034441 patent/WO2004039327A2/en not_active Ceased
- 2003-10-29 US US10/533,045 patent/US20060122262A1/en not_active Abandoned
- 2003-10-29 AU AU2003286781A patent/AU2003286781B2/en not_active Expired
- 2003-10-29 JP JP2004548591A patent/JP4889944B2/ja not_active Expired - Lifetime
-
2009
- 2009-10-02 US US12/572,791 patent/US8153684B2/en not_active Expired - Fee Related
-
2011
- 2011-08-12 JP JP2011177316A patent/JP5535999B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-09 US US13/442,466 patent/US8450364B2/en not_active Expired - Fee Related
-
2013
- 2013-05-28 US US13/903,748 patent/US9089547B2/en not_active Expired - Lifetime
-
2015
- 2015-07-27 US US14/810,117 patent/US9408825B2/en not_active Expired - Fee Related
-
2016
- 2016-03-09 US US15/065,344 patent/US9889116B2/en not_active Expired - Fee Related
-
2018
- 2018-01-03 US US15/861,386 patent/US10111855B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508942A5 (https=) | ||
| Singh et al. | Melatonin: functions and ligands | |
| EP1196163B1 (en) | Pharmaceutical compositions for the treatment of insulin resistance | |
| Sahu et al. | Pharmacological activities of dehydroepiandrosterone: a review | |
| Anagnostis et al. | 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? | |
| US20100029784A1 (en) | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties | |
| CA2564399A1 (en) | Use of equol for treating skin diseases | |
| JP2007534751A5 (https=) | ||
| WO2010005989A1 (en) | Dermatological compositions with anti-aging and skin even-toning properties | |
| BR0300156A (pt) | Método de medição do nìvel de estresse ou relaxamento de um mamìfero | |
| JP2009535331A (ja) | 細胞増殖および血管新生を特徴とする皮膚疾患の治療用組成物および方法 | |
| Ohnemus et al. | Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to damage | |
| BG62756B1 (bg) | Метод за лечение на андрогенна алопеция с инхибитори на 5-алфа редуктаза | |
| AU2008323198B2 (en) | C-19 steroids for cosmetic and further uses | |
| Shih | Activation of estrogen receptor β-dependent nitric oxide signaling mediates the hypotensive effects of estrogen in the rostral ventrolateral medulla of anesthetized rats | |
| JP6025301B2 (ja) | 治療上の使用のためのｃ−１９ステロイド | |
| Pan et al. | Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation | |
| US20180344685A1 (en) | Compositions and methods for increased glucose uptake and fat metabolism | |
| Hutchins et al. | Hypertensive crisis associated with high dose soy isoflavone supplementation in a post-menopausal woman: a case report [ISRCTN98074661] | |
| US5609858A (en) | Method for treatment of androgenic alopecia | |
| JP2003519647A (ja) | 皮膚の傷んだ外観の改善のためのｄｈｅａ及び／またはその前駆体または誘導体の使用 | |
| US9364455B2 (en) | Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders | |
| CA2809793C (en) | Treatment of fungal infections | |
| CN101043816A (zh) | 泽泻在化妆品及其组合物中的应用 | |
| WO1996015783A1 (en) | Method for topical treatment of androgenic alopecia |